MedicureSTU:NGQ1 +0.81%57 EBITDA Margin % is 3.49% as of Mar. 2026, which is 62% below its 10-year median of 9.09. GuruFocus rates STU:NGQ1 with a GF Score™ of 57/100 and a GF Value™ of €0.76. The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Medicure ranks worse than 82.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medicure's EBITDA for the
three
months ended in Mar. 2026 was €0.18 Mil. Medicure's Revenue for the
three
months ended in Mar. 2026 was €5.01 Mil. Therefore, Medicure's EBITDA margin for the quarter that ended in Mar. 2026 was 3.49%.
Medicure (STU:NGQ1) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medicure EBITDA Margin % Related Terms
Medicure EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medicure's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medicure's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicure (STU:NGQ1) has a EBITDA Margin % of 3.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicure and its competitors. This is 62% below median its historical median of 9.09. According to the industry distribution chart, Medicure ranks #786 out of 956 companies in the Drug Manufacturers industry, placing it in the top 82.2%.
Is Medicure's EBITDA Margin % too high?
Medicure's current EBITDA Margin % of 3.49% is 62% below median its 10-year median of 9.09. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Medicure's value of 3.49% is 72.1% below this industry median. Based on the distribution chart, Medicure ranks #786 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicure has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Medicure's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #786 out of 956 companies for EBITDA Margin %. This places Medicure in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Medicure's value of 3.49% is 72.1% below this benchmark. While the company's 10-year median is 9.09 vs. the industry median of 12.52, Medicure has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicure's current EBITDA Margin % of 3.49% is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicure and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current EBITDA Margin % is 3.49%, which is 62% below median its own 10-year median of 9.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Medicure (STU:NGQ1) has a current EBITDA Margin % of 3.49%. The stock's GF Value™ is €0.76, compared to a current price of €0.63 — trading 17.8% below its estimated fair value. The current EBITDA Margin % is 3.49%, which is 62% below median its 10-year median of 9.09 and 72.1% below the Drug Manufacturers industry median of 12.52. Medicure's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medicure (STU:NGQ1), the current EBITDA Margin % is 3.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (STU:NGQ1) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of €0.63 is trading 17.8% below its estimated GF Value™ of €0.76.
Key valuation signals for STU:NGQ1:
EBITDA Margin %: 3.49% (62% below median its 10-year median of 9.09)
GF Value™: €0.76 vs. price of €0.63 (17.8% below fair value)
Industry Position: 72.1% below the Drug Manufacturers median (#786 of 956)
No single metric tells the full story. See the STU:NGQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
57GF Score
Get the complete analysis for STU:NGQ1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NGQ1 has been successfully added to your 
